Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Immune-related adverse events
•
Neurology
•
Neuromuscular
How do you manage immunotherapy-induced myasthenia gravis?
Answer from: at Academic Institution
My go-to algorithm is well-represented in the paper by Dr. @Adeel Zubair et al. Zubair et al., PMID 36439604
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
NCCN "Management of Immunotherapy-Related Toxicities" has a useful 'cheat sheet' as a quick reference for the overnight call.
Sign in or Register to read more
19074
19390
Related Questions
What is your approach to a child with toe walking with a reassuring exam but a family history of difficulty walking?
Do you utilize phrenic nerve EMG in patients with diaphragmatic issues?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
What workup do you recommend for patients with symptoms suggestive of saphenous neuropathy?
When do you initiate migalastat in female patients with genetic evidence of heterozygous Fabry disease?
At what point do you consider weaning steroids or immuno-modulating agents in patients with Myasthenia Gravis?
What is the expected timeframe for the development of radiation myelitis and therapies that have helped with neurologic symptoms?
How do you dose gabapentin in patients with renal failure?
Would you add immunosuppression in ocular myasthenia gravis patients who are symptomatically well-controlled on pyridostigmine?
How do you approach patients with positive LRP4 antibodies without clinical findings of myasthenia gravis?